---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-011511"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:44:39.683878+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q1 revenue $36.2M (+115% YoY); net loss $7.1M vs $1.1M

## Summary
- GAAP EPS -$0.17 vs -$0.03; adjusted EBITDA -$814K vs +$2.8M a year ago.
- Organic revenue growth 45%; biopreservation media revenue up 53%.
- Gross margin GAAP 29%, adjusted 33%; improved sequentially from Q4 2021.
- FY22 revenue guidance reaffirmed $159.5-$171M (34-44% growth); expects positive adj. EBITDA.
- Management & board to accept shares in lieu of cash compensation.

## SEC filing metadata
- accession: 0001437749-22-011511
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000143774922011511/0001437749-22-011511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000143774922011511/bioli20220509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-011511
- JSON: https://secwatch.observer/filing/0001437749-22-011511.json
- Plain text: https://secwatch.observer/filing/0001437749-22-011511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.